These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 35680060)
41. 3-Bromopyruvate alleviates the development of monocrotaline-induced rat pulmonary arterial hypertension by decreasing aerobic glycolysis, inducing apoptosis, and suppressing inflammation. Liu J; Wang W; Wang L; Qi XM; Sha YH; Yang T Chin Med J (Engl); 2020 Jan; 133(1):49-60. PubMed ID: 31923104 [TBL] [Abstract][Full Text] [Related]
42. Soluble guanylate cyclase stimulator, trans-4-methoxy-β-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats. Gonzaga-Costa K; Vasconcelos-Silva AA; Rodrigues-Silva MJ; Rebouça CDSM; Duarte GP; Borges RS; Magalhães PJC; Lahlou S Eur J Pharmacol; 2021 Apr; 897():173948. PubMed ID: 33609564 [TBL] [Abstract][Full Text] [Related]
45. Influence of imatinib at a low dose and sildenafil on pulmonary hypertension in rats. Jasińska-Stroschein M; Owczarek J; Cicha K; Orszulak-Michalak D Pharmazie; 2015 Jul; 70(7):477-9. PubMed ID: 26373209 [TBL] [Abstract][Full Text] [Related]
46. [Effect of sesamin on pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary hypertension]. Li XW; Gao YX; Li S; Yang JR Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(7):1355-61. PubMed ID: 26281561 [TBL] [Abstract][Full Text] [Related]
47. Overexpressed pigment epithelium-derived factor alleviates pulmonary hypertension in two rat models induced by monocrotaline and SU5416/hypoxia. Miao H; Hui H; Fan W; Lin Y; Li H; Li D; Luo M; Qiu F; Jiang B; Zhang Y Biomed Pharmacother; 2024 Mar; 172():116303. PubMed ID: 38377738 [TBL] [Abstract][Full Text] [Related]
48. 2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Tofovic SP; Zhang X; Zhu H; Jackson EK; Rafikova O; Petrusevska G Vascul Pharmacol; 2008; 48(4-6):174-83. PubMed ID: 18373958 [TBL] [Abstract][Full Text] [Related]
49. The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling. Zeng Z; Li Y; Jiang Z; Wang C; Li B; Jiang W Cardiovasc Ther; 2010; 28(1):23-9. PubMed ID: 20074256 [TBL] [Abstract][Full Text] [Related]
50. Chrysin Alleviates Monocrotaline-Induced Pulmonary Hypertension in Rats Through Regulation of Intracellular Calcium Homeostasis in Pulmonary Arterial Smooth Muscle Cells. Dong F; Zhang J; Chen X; Zhang S; Zhu L; Peng Y; Guo Z J Cardiovasc Pharmacol; 2020 Jun; 75(6):596-602. PubMed ID: 32168153 [TBL] [Abstract][Full Text] [Related]
51. 5-Aminosalicylic Acid Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats by Increasing the Expression of Nur77. Sun LY; Cai ZY; Pu J; Li J; Shen JY; Yang CD; He B Inflammation; 2017 Jun; 40(3):806-817. PubMed ID: 28213866 [TBL] [Abstract][Full Text] [Related]
52. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844 [TBL] [Abstract][Full Text] [Related]
53. Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling. Zhu Y; Wu Y; Shi W; Wang J; Yan X; Wang Q; Liu Y; Yang L; Gao L; Li M Life Sci; 2017 Mar; 173():36-42. PubMed ID: 28212825 [TBL] [Abstract][Full Text] [Related]
54. Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of SphK1-mediated NF-κB activation. Shi W; Zhai C; Feng W; Wang J; Zhu Y; Li S; Wang Q; Zhang Q; Yan X; Chai L; Liu P; Chen Y; Li M Life Sci; 2018 Oct; 210():140-149. PubMed ID: 30179628 [TBL] [Abstract][Full Text] [Related]
55. Matrix metalloproteinases are possible targets in monocrotaline-induced pulmonary hypertension: investigation of anti-remodeling effects of alagebrium and everolimus. Atlı Ö; Ilgın S; Ergun B; Burukoğlu D; Musmul A; Sırmagül B Anatol J Cardiol; 2017 Jan; 17(1):8-17. PubMed ID: 27182612 [TBL] [Abstract][Full Text] [Related]
56. Docosahexaenoic acid inhibits monocrotaline-induced pulmonary hypertension via attenuating endoplasmic reticulum stress and inflammation. Chen R; Zhong W; Shao C; Liu P; Wang C; Wang Z; Jiang M; Lu Y; Yan J Am J Physiol Lung Cell Mol Physiol; 2018 Feb; 314(2):L243-L255. PubMed ID: 29097423 [TBL] [Abstract][Full Text] [Related]
57. Pulmonary Artery Hypertension Model in Rats by Monocrotaline Administration. Bueno-Beti C; Sassi Y; Hajjar RJ; Hadri L Methods Mol Biol; 2018; 1816():233-241. PubMed ID: 29987824 [TBL] [Abstract][Full Text] [Related]
58. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling. Cheng G; Wang X; Li Y; He L Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784 [TBL] [Abstract][Full Text] [Related]